PPD
JULY 6, 2023
It’s estimated that nearly three out of every four clinical trials are conducted by contract research organizations (CROs), highlighting just how much sponsors value — and rely on — the work that CROs perform. As clinical trials become more complex, sponsors are seeking business partnerships with a congruency in the management and prioritization of pipeline.
Drug Discovery World
JULY 5, 2023
Mark Garner, PhD., Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research. RA: Please can you tell us a bit more about your role at Agilent? MG: I am responsible for Agilent’s cancer segment. You could describe my role as being a convener across all our cancer research-related product lines, our Medical Affairs team, and the rest of the organisation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
JULY 4, 2023
Over the last two decades, an increasing number of Antibody Drug Conjugate (ADC) therapeutics have been approved for oncology indications. These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Through their unique modes of action, ADCs have been heralded as having the potential to positively impact not only cancer patient outcomes but also quality of life, an increasingly important factor in treatment decisions for t
BioPharma Drive: Drug Pricing
JULY 6, 2023
Five years after helping launch Allogene Therapeutics, Pfizer is backing another developer of “off-the-shelf” cell therapies in a deal that gives the drugmaker the chance to acquire a multiple myeloma treatment.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drugs.com
JULY 5, 2023
WEDNESDAY, July 5, 2023 -- A new blood test approved by the U.S. Food and Drug Administration can predict imminent preeclampsia, helping pregnant women who are at risk for this severe and sometimes deadly form of high blood pressure. The test can.
Drug Discovery World
JULY 5, 2023
The Summer 2023 issue of Drug Discovery World Magazine is out now and includes an exclusive guide on Therapeutic Antibodies. Featuring a Therapeutic Spotlight on Immuno-oncology , the magazine is available to download free here and read for free on the DDW App. You can also request to receive a copy of the printed magazine here. Key features of the Summer issue include a market report on India’s drug discovery sector, advancing treatments in Alzheimer’s, and whether big data can chart
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
BioPharma Drive: Drug Pricing
JULY 5, 2023
Phase 2 results show a pill the company is developing is competitive with other oral medicines in testing against psoriasis, among them the TYK2 inhibitors that have drawn significant industry interest.
Drugs.com
JULY 5, 2023
WEDNESDAY, July 5, 2023 -- For nearly three decades, daily antiretroviral pills have offered patients living with HIV a highly effective way to keep their infection under control. But some patients, particularly those beset by homelessness, drug.
Drug Discovery World
JULY 4, 2023
New data from Boehringer Ingelheim and Zealand Pharma has demonstrated superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment. The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, US.
Perficient: Drug Development
JULY 4, 2023
A small tip can be a lifesaver when it comes to customizing a platform or an existing system. It’s crucial to first grasp the implementation details and then follow the correct path to add new functionality or make changes to existing features. However, if you’re unfamiliar with a particular area of the system and are tasked with making a specific change, it can be time-consuming to identify where to start and exactly where to make the necessary modifications to meet the requirement.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
ProRelix Research
JULY 6, 2023
Biosimilar clinical trials and study designs’ Considerations The rising prevalence and large market share of biological products emphasize their importance as treatment options for several cancers and autoimmune diseases. In […] The post Biosimilar clinical trials and study designs’ considerations appeared first on ProRelix Research.
Drugs.com
JULY 6, 2023
THURSDAY, July 6, 2023 -- Curious about what the differences are between hepatitis A, B, C, D and E? If so, you’ve come to the right place. Here, experts break down hepatitis infection by type to reveal what it is, the most common symptoms, how.
Drug Discovery World
JULY 7, 2023
Frequent and diverse use of antibiotics may be associated with developing more severe outcomes after a Covid-19 infection, including death, UK scientists have shown. The findings, funded by Health Data Research UK and the National Institute for Health and Care Research (NIHR), act as a warning against the overuse of antibiotics in people. The team was led by University of Manchester and included researchers from the Universities of Oxford and Leeds.
Drug Target Review
JULY 5, 2023
What is a microscopy tech centre and how do they assist drug discovery research? We work in a unique shared facility that is completely open access, meaning our tech centre is open to anyone and everyone, regardless of affiliation or experience. Our goal is to provide easy access to multimillion-dollar microscopes that would otherwise be unavailable to a lot of researchers.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Science Daily: Pharmacology News
JULY 4, 2023
A detailed analysis of the dietary habits of elephants showed surprising variation from meal to meal, which could have important ramifications for wildlife protection and conservation strategies.
Drugs.com
JULY 6, 2023
THURSDAY, July 6, 2023 -- Did you know the U.S. Centers for Disease Control and Prevention estimates that there were nearly 68,000 new cases of acute hepatitis C in 2020 and over 107,000 newly reported cases of chronic hepatitis C? To help you.
Drug Discovery World
JULY 7, 2023
News round-up for 3-7 July by DDW Digital Content Editor Diana Spencer. It’s been a fascinating week in drug discovery, as AstraZeneca announced that its Phase III trial of datopotamab deruxtecan did not meet its second primary endpoint and saw an 8% drop in its stock market value as a result. In other headline news, the FDA approved the first cellular therapy for type 1 diabetes which could allow some patients to become insulin-independent, and a new study linked severe Covid-19 outcomes with h
Drug Target Review
JULY 6, 2023
TPD is a rapidly evolving therapeutic modality to degrade a disease-causing proteins, thereby eliminating their function specifically. 1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. Unlike traditional drug discovery, which focuses on inhibiting or activating proteins, TPD offers a more precise and efficient way to alter cellular pathways. 1 The concept of TPD was first demonstrated with a heterobifunctional small molecu
Antidote
JULY 5, 2023
Breast cancer as defined by the Centers for Disease Control and Prevention (CDC) is “a disease in which cells in the breast grow out of control.” It is the second leading cause of cancer-related death in women, and approximately 264,000 new cases are diagnosed in the United States each year.
Drugs.com
JULY 7, 2023
FRIDAY, July 7, 2023 -- An experimental implant now under development could serve as a temporary monitor and pacemaker for ailing heart patients -- then dissolve away when it’s no longer needed. The soft, lightweight and transparent implant.
Drug Discovery World
JULY 7, 2023
The results of a preclinical study supporting the antidepressive effects of AlzeCure Pharma’s NeuroRestore ACD856 have been published in the journal Psychopharmacology. The article focuses on new data showing that ACD856, the lead and clinical drug candidate in the NeuroRestore platform, exhibits antidepressant effects in various preclinical models.
Drug Target Review
JULY 5, 2023
Drug Target Review’s Taylor Mixides interviews Cellarity’s CEO Fabrice Chouraqui about applying Artificial Intelligence (AI) and Machine Learning (ML) to evolving single-cell technologies. Cells are the units of life, yet they also drive disease. By applying AI/ML to the evolving gamut of single-cell technologies, we can better understand how cells transition from a state of health to disease.
Drug Patent Watch
JULY 2, 2023
Annual Drug Patent Expirations for LEVITRA Levitra is a drug marketed by Bayer Hlthcare and is included in one NDA. There are two patents protecting this drug and three Paragraph… The post New patent expiration for Bayer Hlthcare drug LEVITRA appeared first on DrugPatentWatch - Make Better Decisions.
Drugs.com
JULY 5, 2023
WEDNESDAY, July 5, 2023 -- Heather Anderson, a star Australian rules football player who died last November, is the first female professional athlete to be diagnosed with chronic traumatic encephalopathy, or CTE. "She is the first female athlete.
Drug Channels
JULY 7, 2023
Today’s guest post comes from Sahil Naik, Chief of Staff to the CEO at Phil, Inc. Sahil discusses how manufacturers can balance patients’ access to therapy with gross-to-net (GTN) goals. Visit [link] to learn more about how Phil helps improve the patient experience while managing GTN. Read on for Sahil’s insights. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.
Drug Target Review
JULY 4, 2023
In this article from Drug Target Review , the groundbreaking utilisation of tomographic phase microscopy in flow cytometry is examined, showcasing its ability to accurately measure intracellular lipid droplets in three dimensions without the need for labelling. The researchers have successfully demonstrated the high-throughput capabilities of this label-free technique.
Broad Institute
JULY 6, 2023
More diverse datasets lead to better genetic risk prediction for heart disease By Leah Eisenstadt July 6, 2023 Breadcrumb Home More diverse datasets lead to better genetic risk prediction for heart disease By using genetic data on multiple traits from people of non-European ancestry, scientists have improved the accuracy of polygenic scores in predicting disease risk for all.
Drugs.com
JULY 4, 2023
TUESDAY, July 4, 2023 -- Bacteria found in hospital patients in Ukraine is showing extreme antibiotic resistance, making it harder to treat the wounded and ill in this war-torn country, new research warns. “I am quite thick-skinned and have.
biobide
JULY 7, 2023
Water quality is of utmost importance for the environment as it directly impacts the health and well-being of ecosystems, aquatic life, and the human population. Water quality is especially relevant as it is present in all ecosystems, affecting the whole ecosystem’s health and balance, including species biodiversity, crop irrigation, and drinking water supply.
Drug Target Review
JULY 3, 2023
There is a significant unmet need for effective treatments to alleviate suffering and prevent premature death across the spectrum of genetic diseases. Unfortunately, the majority of genetic diseases lack a cure, leaving limited therapeutic options available. While existing treatments can help manage symptoms, reduce complications, and slow disease progression in certain cases, they do not offer lasting cures for most genetic disorders.
Perficient: Drug Development
JULY 3, 2023
Perficient has once again been named a Best Place to Work in Orange County. Not to mention, this is our fifth consecutive year being recognized! Winning this award yet again means so much to our Southern California team because not only does it serve as a reminder of our constant commitment to excellence, but this award also reflects the strength of our company culture, one that challenges and champions great people.
Drugs.com
JULY 6, 2023
THURSDAY, July 6, 2023 -- Stimulant medications like Ritalin are commonly prescribed to help treat the symptoms of attention deficit hyperactivity disorder, but there have been concerns the drugs may lay the groundwork for later substance abuse. New.
SCIENMAG: Medicine & Health
JULY 7, 2023
July 7, 2023 – Patients undergoing bilateral total knee arthroplasty (TKA) are at an increased risk of several types of complications, as compared with matched patients undergoing unilateral TKA, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
Drug Target Review
JULY 3, 2023
Dr David Baram from gene therapy company EmendoBio provides a snapshot of the history of therapeutic genetic engineering, explaining the early pitfalls and reasons for recent renewed optimism. A long and winding path The early years of gene therapy were characterised by an era of overwhelming optimism, with many believing that advances in DNA manipulation would mean the realisation of curative therapies for multiple disease states.
Expert insights. Personalized for you.
98 
Let's personalize your content